Dr. Reddy s Labs launches Ertapenem for Injection in the US Market
Mumbai, May 12 (UNI) Dr Reddy s Labs on Wednesday on Wednesday announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the US Food and Drug Administration (USFDA). We are pleased to bring this important product to market at this time, says Marc Kikuchi, CEO, North America Generics, Dr. Reddy s Laboratories. We re excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr Reddy s, has enabled the execution of this launch.
Dr. Reddy s Laboratories Launches Generic Version Of INVANZ In US
WASHINGTON (dpa-AFX) - Dr. Reddy s Laboratories (RDY) Wednesday announced the launch of Ertapenem for Injection 1 g/vial, a generic version of Invanz, in the U.S. market.
Dr. Reddy s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.
Merck s Invanz and generic market had U.S. sales of about $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health. We re excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr. Reddy s, has enabled the execution of this launch, said Marc Kikuchi, CEO, North America Generics, Dr. Reddy s Laboratories.
Dr Reddy’s to manufacture Baricitinib drug for Covid treatment
The drug baricitinib has received restricted emergency use approval from the CDSCO, for use in combination with Remdesivir for COVID-19 treatment.
By IANS| Updated: 12th May 2021 11:26 am IST entered into a royalty-free, non-exclusive voluntary licensing agreement for the same. (Photo: Company Logo)
Hyderabad: Pharma major Dr. Reddy’s Laboratories Ltd on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of Baricitinib in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporea
Dr Reddy s launches generic Invanz injection in US market dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.
Dr Reddy s to manufacture baricitinib for Covid treatment
By IANS |
Published on
Wed, May 12 2021 11:03 IST |
3 Views
Mumbai Port Trust to sign MoUs of worth Rs 1,860 cr at Maritime Summit. Image Source: IANS News
Hyderabad, May 12 : Pharma major Dr. Reddy s Laboratories Ltd on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of baricitinib in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).